Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial AK105 in selected advanced solid tumors has completed Phase 1/2; the summary does not provide efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Lung Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)

Snippet

Sponsor: Akeso | Conditions: Solid Tumor, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED